Page 96 - Read Online

Saleh et al. Improvement of prostate cancer detection

these serum markers and the aggressiveness of the specific antigen (PSA) screening and new biomarkers for prostate
PCa, either in terms of the pathological stage or of the cancer (PCa). EJIFCC 2014;25:55-78.
Gleason score. 10. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA:
the next generation of prostate cancer biomarkers. Sci Transl Med
2012;4:127rv3.
Authors’ contributions 11. Weroha SJ, Haluska P. IGF system in cancer. Endocrinol Metab Clin
All authors equally contributed to this study. North Am 2012;41:335-50.
12. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer:
Financial support and sponsorship from basic to clinical studies and clinical applications. Oncology
None. 2002;63:317-32.
13. Hamelers IH, Van Schaik RF, Sipkema J, Sussenbach JS, Steenbergh
Conflicts of interest PH. Insulin-like growth factor I triggers nuclear accumulation
There are no conflicts of interest. of cyclin D1 in MCF-7S breast cancer cells. J Biol Chem
2002;277:47645-52.
Patient consent 14. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-
like growth factor-binding protein 2 and 5 are differentially
Patient consent was obtained from all participants. All regulated in ovarian cancer of different histologic types. Mod Pathol
participants were informed of the aim and procedures 2006;19:1149-56.
and were assured that they could discontinue their 15. Luo SM, Tan WM, Deng WX, Zhuang SM, Luo JW. Expression of
participation in the study without any effect on the albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor
medical care provided to them. tissues of hepatocellular carcinoma patients with cirrhosis. World J
Gastroenterol 2005;11:4272-6.
Ethics approval 16. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding
The Ethical Research Committee at the Faculty of proteins in serum and other biological fluids: regulation and functions.
Endocr Rev 1997;18:801-31.
Medicine, Umm Al Qura University, and affiliated 17. LeRoith D, Roberts CT Jr. The insulin like growth factor system and
hospitals approved this study. Informed consent was cancer. Cancer Lett 2003;195:127-37.
obtained from all patients and healthy subjects; the aim 18. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate
of the study and the procedures that would be required cancer. Recent Results Cancer Res 2003;164:205-21.
were described to them beforehand. All subjects were 19. Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel insights
assured that they could choose to discontinue their into the implication of the IGF-1 network in prostate cancer. Trends
Mol Med 2005;11:52-5.
participation in the study without jeopardizing the 20. Djavan B, Amir Kazzazi A, Dulabon L, Margreiter M, Farr A, Handl
medical care being given to them, including treatment MJ, Lepor H. Diagnostic strategies for prostate cancer. Eur Urol
and follow-up. Suppl 2011;10:26-37.
21. Berrigan D, Potischman N, Dodd KW, Hursting SD, Lavigne J,
REFERENCES Barrett JC, Ballard-Barbash R. Race/ethnic variation in serum
levels of IGF-I and IGFBP-3 in US adults. Growth Horm IGF Res
1. Cancer Facts and Figures 2017. Atlanta, GA: American Cancer 2009;19:146-55.
Society; 2017. 22. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger
2. Mahmood A, Te OB, Urcia JC, Khan A. Tumor registry annual M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and
report 2011. Riyadh: King Faisal Specialist Hospital and Research cancer risk: systematic review and meta-regression analysis. Lancet
Center; 2012. 2004;363:1346-53.
3. International Agency for Research on Cancer (IARC) (2012) [cited 23. Colombo B, Curnis F, Foglieni C,Monno A, Arrigoni G, Corti A.
2016 December 9]. Prostate Cancer, Estimated Incidence, Mortality Chromogranin A expression in neoplastic cells affects tumor growth
and Prevalence Worldwide. Available from: http://globocan.iarc.fr/old/ and morphogenesis in mouse models. Cancer Res 2002;62:941-6.
FactSheets/cancers/prostate-new.asp#INCIDENCE. [Last accessed on 24. Yang X, Yang Y, Li Z, Cheng C, Yang T, Wang C, Liu L, Liu S. Diagnostic
May 16, 2017] value of circulating chromogranin a for neuroendocrine tumors: a
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J systematic review and meta-analysis. PLoS One 2015;10:e0124884.
Clin 2017;67:7-30. 25. Ferrero-Poüs M, Hersant AM, Pecking A, Brésard-Leroy M, Pichon
5. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific MF. Serum chromogranin-A in advanced prostate cancer. BJU Int
antigen: alternate serum markers. Prostate Cancer Prostatic Dis 2001;88:790-6.
2008;11:216-29. 26. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, Tarabuzzi
6. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor R, Bollito E, Fontana D, Angeli A. Circulating neuroendocrine
markers. Am Fam Physician 2003;68:1075-82. markers in patients with prostate carcinoma. Cancer 2000;88:2590-7.
7. Theodorescu D, Krupski TL (2009) [Cited 2016 December 12]. 27. Fracalanza S, Prayer-Galetti T, Pinto F, Navaglia F, Sacco E, Ciaccia
Prostate Cancer: Biology, Diagnosis, Pathology, Staging and M, Plebani M, Pagano F, Basso D. Plasma chromogranin A in patients
Natural History. Available from: http://emedicine.medscape.com/ with prostate cancer improves the diagnostic efficacy of free/total
article/458011-overview. [Last accessed on May 16, 2017] prostate-specific antigen determination. Urol Int 2005;75:57-61.
8. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating 28. Grimaldi F, Valotto C, Barbina G, Visentini D, Trianni A, Cerruto
biomarkers for prostate cancer. Prostate Cancer Prostatic Dis MA, Zattoni F. The possible role of chromogranin A as a prognostic
2008;11:112-20. factor in organ-confined prostate cancer. Int J Biol Markers
9. Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K. Prostate- 2006;21:229-34.
88 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ May 24, 2017